Skip to main content

Table 3 Subgroup analyses on the primary outcome (death due to acute pancreatitis)

From: Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis

No Subgroup Trial (n) Citations Effectiveness Heterogeneity
1 High-quality 6 [31, 34, 35, 37, 46, 47] No significant Moderate
2 Aprotinin 11 [2729, 3137, 41] No significant Low
3 Gabexate mesilate 6 [4244, 46, 47, 49] No significant Low to moderate
4 Gabexate mesilate daily administrated dosage>900mg 5 [42, 44, 46, 47, 49] No significant Low to moderate
5 Gabexate mesilate daily administrated dosage>1500mg 2 [47, 49] No significant Low to moderate
6 Trials with CMR0.10 7 [29, 3133, 37, 42, 46] No significant Low to moderate
7 Trials with CMR>0.10 10 [27, 28, 3436, 41, 43, 46, 47, 49] No significant Low to moderate
8 Trials with CMR>0.20 2 [34, 49] No significant Low to moderate
9 Trials with industrial support 9 [27, 29, 31, 34, 35, 37, 4143] No significant Low to moderate
10 Trials with industrial support 8 [28, 32, 33, 36, 44, 46] No significant Low to moderate
  1. High-quality was defined as Jadad score>3 points; CMR control mortality rate.